Protocol Ledger

NCT06717152 · Phase III · COMPLETED

Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease

Interventional Phase III clinical trial protocol NCT06717152 sponsored by Senju Pharmaceutical Science & Technology (Beijing) Co in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-30 Enrollment: 427 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06717152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)427 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06717152
Protocol FieldVerified Registry Value
NCT IdentifierNCT06717152
Consolidated Lead SponsorSenju Pharmaceutical Science & Technology (Beijing) Co
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment427 participants (ACTUAL)
Registered Start Date2024-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06717152
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Shenzhen HospitalShenzhen, ChinaOpen Hospital Dossier ->
Shenzhen People's HospitalShenzhen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI